ClinicalTrials.gg
RecruitingNCT07659678Updated Oct 7, 2026

CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma

A Phase 2 interventional study of 64Cu-DOTA-ECL1i in Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) and Head and Neck Squamous Cell Carcinoma HNSCC, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Washington University School of Medicine · Phase 2, Interventional, and Diagnostic

How we know

Updated Oct 7, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies in Squamous Cell Carcinoma of Head and Neck by Washington University School of Medicine — 6 open to participants now, 12 under way, 1 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Washington University School of Medicine.

Planned enrollment
3rd of 23
90 · median 43
Started
2026
with 4 others
Phase 2
16 of 24
4 open now
Primary completion
2032-05
later than 11 of 11 live
Registered
22nd of 24
by date

Among the 24 studies in Squamous Cell Carcinoma of Head and Neck by Washington University School of Medicine, this one is the 3rd largest by planned enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2026, is one of 16 in phase 2, reaches primary completion later than 11 of the 11 other live ones, and was the 22nd registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

6 of the 24 studies in Squamous Cell Carcinoma of Head and Neck by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Squamous Cell Carcinoma of Head and Neck by Washington University School of Medicine, or all of them as a file.
02

Study summary

This is a prospective study to evaluate the sensitivity and specificity of Cu-64 DOTA-ECL1i PET/CT imaging to serve as a novel precision imaging tool for patients with head and neck squamous cell carcinoma (HNSCC).

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma
  • Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
  • Head and Neck Squamous Cell Carcinoma HNSCC

Keywords

  • Head and neck cancer
  • P16+ and P16-
  • PET
  • CCR2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient 18 years of age or older
  • Cohort 1: Newly diagnosed locally advanced T3-T4a, N0-3 and M0 squamous cell head and neck cancer scheduled to undergo standard of care surgery with or without therapy OR Cohort 2: Suspected or proven recurrent/ squamous cell head and neck cancer scheduled to undergo anti-PD1 therapy. HPV status does not need to be known and both HPV+ and HPV- subjects are eligible to enroll
  • Lesion size of at least 1.0 cm in longest dimension by conventional imaging.
  • Able to give
  • Not currently pregnant or nursing: Female subjects must be surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), post- menopausal (cessation of menses for more than 1 year), non-lactating, or of for whom a urine pregnancy test (with the test performed within the 24 hour period immediately prior to administration of Cu-DOTA-ECL1i is negative

Exclusion criteria

Exclusion Criteria:

  • Patients with other invasive , with the exception of non-melanoma skin cancer, who had (or have) any evidence of the other cancer present within the last 2 years
  • Unable to tolerate approximately 60 min (total time) of PET/CT imaging
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Newly Diagnosed HNSCC who are scheduled to undergo surgical resection

    Cohort 1 will undergo 64Cu-DOTA-ECL1i positron emission tomography-computed tomography (PET/CT) once prior to scheduled standard of care (SOC) surgery and prior to any neoadjuvant therapy. Participants will be followed up via a phone call or in-person visit 24 hours - 14 days after 64Cu-DOTA-ECL1i administration to assess for adverse events. Participants will be followed via medical chart review for standard of care clinical and radiological appointments.

    Drug: 64Cu-DOTA-ECL1i

  • Experimental
    Cohort 2: Recurrent/metastatic HNSCC who are candidates for first-line anti-PD1 therapy

    Cohort 2 subjects will undergo 64Cu-DOTA-ECL1i PET imaging twice, once at baseline prior to the start of anti-PD1 therapy and after 3 cycles of therapy (within 14 days of cycle 4 day 1). Participants will be followed up via a phone call or in-person visit 24 hours - 14 days after baseline 64Cu-DOTA-ECL1i administration to assess for adverse events. Participants will be followed via medical chart review for standard of care clinical and radiological appointments.

    Drug: 64Cu-DOTA-ECL1i

Interventions

  • DrugCopper Cu 64-DOTA-ECL1iStudies of Copper Cu 64-DOTA-ECL1iCopper Cu 64-DOTA-ECL1i pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    64Cu-DOTA-ECL1i a novel PET imaging tracer that will be provided intravenously (IV) while participants will be positioned supine on the on the scanning table. The injection will be followed with saline flush.

    Also known as: Copper Cu 64-DOTA-ECL1i, 64Cu-d(LGTFLKC), Cu-64 DOTA-ECL1i

06

What researchers measure

Primary outcomes

  1. Cohort 1 only: Semiquantitative 64Cu-DOTA-ECL1i PET/CT uptake

    64Cu-DOTA-ECL1i PET uptake will be assessed using standardized update value maximum (SUVmax). SUV is a decay-corrected measurement of activity per volume of tissue (µCi/mL) divided by the average activity per unit mass in the entire body and/or tumor-to-normal-tissue-ratio. SUVmax is the highest measured uptake of a tracer of a lesion on a PET scan.

    Time frame: At baseline prior to scheduled surgery (estimated time frame: 1 day)

  2. Cohort 1 only: Quantitative 64Cu-DOTA-ECL1i PET/CT uptake

    Quantitative 64Cu-DOTA-ECL1i PET uptake will be assessed via a Logan/Patlak analysis to characterize the pharmacokinetics of the tumor. Logan/Patlak is a graphical analysis which uses linear regression to analyze the pharmacokinetics of tracers involving reversible uptake.

    Time frame: At time of surgery (total estimated time up to 14 days)

  3. Cohort 2 only: Semiquantitative 64Cu-DOTA-ECL1i PET/CT uptake

    64Cu-DOTA-ECL1i PET uptake will be assessed using standardized update value maximum (SUVmax). SUV is a decay-corrected measurement of activity per volume of tissue (µCi/mL) divided by the average activity per unit mass in the entire body) and/or tumor-to-normal-tissue-ratio. SUVmax is the highest measured uptake of a tracer of a lesion on a PET scan

    Time frame: At baseline (estimated time frame: 1 day)

  4. Cohort 2 only: Quantitative 64Cu-DOTA-ECL1i PET/CT uptake

    Quantitative 64Cu-DOTA-ECL1i PET uptake will be assessed via a Logan/Patlak analysis to characterize the pharmacokinetics of the tumor. Logan/Patlak is a graphical analysis which uses linear regression to analyze the pharmacokinetics of tracers involving reversible uptake.

    Time frame: At time of surgery (total estimated time up to 14 days)

  5. Cohort 1 only: CCR2 expression in tumor tissue

    CCR2 expression will be analyzed in tumor tissue specimens obtained from surgical specimens collected at resection and from archival biopsy specimens obtained prior to neoadjuvant therapy. CCR2 expression will be examined using flow cytometry and RT-PCR.

    Time frame: At time of surgery (total estimated time up to 14 days)

  6. Cohort 2 only: Change in 64Cu-DOTA-ECL1i PET uptake from baseline to post-cycle 3 imaging

    64Cu-DOTA-ECL1i PET uptake will be assessed using standardized update value maximum (SUVmax). SUV is a decay-corrected measurement of activity per volume of tissue (µCi/mL) divided by the average activity per unit mass in the entire body and/or tumor-to-normal-tissue-ratio. SUVmax is the highest measured uptake of a tracer of a lesion on a PET scan.

    Time frame: At baseline and post cycle 3 imaging (estimated time frame up to 9 weeks)

  7. Cohort 2 only: Objective response

    Objective response will be assessed according to RECIST 1.1. Objective response is defined as categorized as responder versus non-responder based on best overall response. Responder is defined as best overall response as complete or partial response. Non-responder is defined as best overall response as stable disease or progressive disease.

    Time frame: Enrollment until date of completion of follow-up, date of disease progression, or time of death, whichever occurs first (estimated total time to be 12 months)

  8. Cohort 2 only: Progression-free survival (PFS)

    PFS is defined from anti-PD1 treatment start date to date of progression or date of death due to any cause. PFS will be analyzed by the Kaplan-Meier method.

    Time frame: Start of anti-PD1 treatment to date of disease progression or death from any cause (total estimated time to be 12 months)

  9. Cohort 2 only: Overall survival (OS)

    OS is defined from start of treatment to death due to any cause or last date of follow up. Alive patients are censored at the last follow-up otherwise. OS will be analyzed by the Kaplan-Meier method.

    Time frame: Start of anti-PD1 treatment to date of death from any cause (total estimated time to be 12 months)

07

Study locations

1 of 1 sites recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Farrokh Dehdashti, MD · Contactdehdashtif@wustl.edu · 314-362-1474
    • Yongjian Liu, PhD · Sub investigator
    • Ryan Jackson, MD · Sub investigator
    • Sidharth Puram, MD, PhD · Sub investigator
    • Douglas Adkins, MD · Sub investigator
    • Ningying Wu, MD, PhD · Sub investigator
    • Chieh-Yu Lin, MD, PhD · Sub investigator
    • Richard Laforest, PhD · Sub investigator
    • Ying Hwey Nai, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data collected during the trial, metadata collection, and supporting files will be shared via the digital repository Digital Commons@Becker.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be available as soon as possible, but no later than the time of publication or the end of the funding period, whichever comes first. The duration of preservation and sharing of the data will be a minimum of 10 years after the funding period.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for May 2032, 67 months later.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 67 months is above that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: start Aug 2026 → Oct 2026, primary completion Mar 2032 → May 2032 and completion Mar 2032 → May 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Jun 22, 2026
StartEst.
Oct 31, 2026was Aug 2026
Primary completionEst.
May 31, 2032was Mar 2032
CompletionEst.
May 31, 2032was Mar 2032
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 7, 2026
Sites
Washington University School of Medicine is now Recruiting
Oct 7, 2026
Start date
Aug 31, 2026→Oct 31, 2026
Oct 7, 2026
Primary completion
Mar 31, 2032→May 31, 2032
Oct 7, 2026
Study completion
Mar 31, 2032→May 31, 2032
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Not yet recruiting→Recruiting
    Washington University School of Medicine is now Recruiting
    Start date Aug 31, 2026→Oct 31, 2026
    Primary completion Mar 31, 2032→May 31, 2032
    Study completion Mar 31, 2032→May 31, 2032

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07659678
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Oct 31, 2026 (estimated)
Primary completion
May 31, 2032 (estimated)
Completion
May 31, 2032 (estimated)
Last update
Oct 7, 2026

Study contacts

Farrokh Dehdashti, MD
Contact
dehdashtif@wustl.edu
314-362-1474
Farrokh Dehdashti, MD
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Copper Cu 64-DOTA-ECL1i

Start the discussion